MedPath

Ozagrel

Generic Name
Ozagrel
Drug Type
Small Molecule
Chemical Formula
C13H12N2O2
CAS Number
82571-53-7
Unique Ingredient Identifier
L256JB984D
Background

Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes.

Indication

用于缺血性脑卒中急性期，蛛网膜下腔出血手术后的脑血管痉挛收缩和伴随的脑缺血症状。

Clinical Trials
Related News

A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Phase 2
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: Placebo
First Posted Date
2012-09-25
Last Posted Date
2014-05-30
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Registration Number
NCT01692145
Locations
🇯🇵

Japan, Tokyo and Other Japanese City, Japan

A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome

Phase 2
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: Placebo
First Posted Date
2011-09-02
Last Posted Date
2013-10-30
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
180
Registration Number
NCT01427816
Locations
🇯🇵

Japan, Tokyo and Other Japanese City, Japan

A Study of KCT-0809 in Patients With Dry Eye Syndromes

Phase 2
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: Placebo
First Posted Date
2010-09-30
Last Posted Date
2011-07-04
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Target Recruit Count
160
Registration Number
NCT01211951
Locations
🇯🇵

Japan, Tohoku, Kanto, Chubu, Kansai, Kyushu region, Japan

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Phase 4
Completed
Conditions
Cerebral Infarction
Interventions
First Posted Date
2005-09-20
Last Posted Date
2013-01-15
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
401
Registration Number
NCT00200356
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy